{"id":1043,"date":"2025-12-16T16:30:52","date_gmt":"2025-12-16T16:30:52","guid":{"rendered":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/12\/16\/sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks\/"},"modified":"2025-12-16T16:30:52","modified_gmt":"2025-12-16T16:30:52","slug":"sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks","status":"publish","type":"post","link":"https:\/\/wickedsister.evit.com.au\/index.php\/2025\/12\/16\/sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks\/","title":{"rendered":"Sanofi\u2019s experimental MS therapy tolebrutinib suffers twin setbacks"},"content":{"rendered":"<p><a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/12\/16\/sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks\/\" title=\"Sanofi&#8217;s experimental MS therapy tolebrutinib suffers twin setbacks\" rel=\"nofollow\"><img loading=\"lazy\" decoding=\"async\" width=\"800\" height=\"400\" src=\"https:\/\/multiplesclerosisnewstoday.com\/wp-content\/uploads\/2025\/12\/Thumbsdown_Circle-800x400.png\" class=\"webfeedsFeaturedVisual wp-post-image\" alt=\"Eight hands are shown giving the &quot;thumbs-down&quot; sign within a red circle.\" style=\"margin: auto;margin-bottom: 15px;max-width: 100%\" data-wp-pid=\"157156\" \/><\/a><\/p>\n<p>Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy tolebrutinib for\u00a0primary progressive multiple sclerosis (PPMS). Meanwhile, a decision from the U.S. Food and Drug Administration (FDA) on tolebrutinib&#8217;s use in nonrelapsing secondary progressive MS (SPMS)\u00a0is likely to be delayed again, the company said. Sanofi had [&#8230;]<\/p>\n<p>The post <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/12\/16\/sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks\/\">Sanofi&#8217;s experimental MS therapy tolebrutinib suffers twin setbacks<\/a> appeared first on <a href=\"https:\/\/multiplesclerosisnewstoday.com\">Multiple Sclerosis News Today<\/a>.<\/p>\n<p><em>Source: <a href=\"https:\/\/multiplesclerosisnewstoday.com\/news-posts\/2025\/12\/16\/sanofis-experimental-ms-therapy-tolebrutinib-suffers-twin-setbacks\/\" rel=\"nofollow noopener\" target=\"_blank\">multiplesclerosisnewstoday.com<\/a><\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Following negative Phase 3 trial results, Sanofi announced that it will not be pursuing approval of its experimental therapy tolebrutinib for\u00a0primary progressive multiple sclerosis (PPMS). Meanwhile, a decision from the U.S. Food and Drug Administration (FDA) on tolebrutinib&#8217;s use in nonrelapsing secondary progressive MS (SPMS)\u00a0is likely to be delayed again, the company said. Sanofi had&#8230;<\/p>\n","protected":false},"author":0,"featured_media":1044,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[4],"tags":[11,15,9,8,13,14,12,10],"class_list":["post-1043","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-multiple-sclerosis-research","tag-brain-repair","tag-marburg-type-ms","tag-ms","tag-multiple-sclerosis","tag-myelin","tag-neuroregeneration","tag-oligodendrocyte","tag-remyelination"],"_links":{"self":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/comments?post=1043"}],"version-history":[{"count":0,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/posts\/1043\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media\/1044"}],"wp:attachment":[{"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/media?parent=1043"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/categories?post=1043"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/wickedsister.evit.com.au\/index.php\/wp-json\/wp\/v2\/tags?post=1043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}